Form 4: Kezar Life Sciences Director Graham Cooper Granted 5,000 Stock Options

Kezar Life Sciences, Inc. Director Graham K. Cooper was granted 5,000 stock options with an exercise price of $4.46 per share, vesting in June 2026.

Summary

• Graham K. Cooper, a Director of Kezar Life Sciences, Inc. (KZR), acquired 5,000 stock options.
• The transaction date for this acquisition was June 18, 2025.
• Each stock option has an exercise price of $4.46.
• The options are for 5,000 shares of Kezar Life Sciences Common Stock.
• One hundred percent (100%) of the shares subject to the option will vest on June 18, 2026, contingent upon Mr. Cooper's continued service to the company.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Mr. Cooper beneficially owns 5,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally viewed as neutral to slightly positive as it aligns director interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 17, 2035), providing ample time for the stock price to potentially appreciate above the exercise price.

Future Outlook

The vesting schedule indicates that the director's full ownership of these options is contingent on continued service through June 18, 2026, implying an expectation of ongoing commitment.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and life sciences industry, serving as a form of long-term incentive compensation and a mechanism to align the interests of board members with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and board compensation packages across various industries, including biotechnology.
• The vesting schedule, contingent on continued service, is a typical feature designed to retain key personnel and ensure long-term commitment.

Related Party Transactions

• The transaction involves the grant of stock options from Kezar Life Sciences, Inc. to Graham K. Cooper, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options are scheduled to vest on June 18, 2026, provided the reporting person continues to provide service.

Key Dates

Keywords

Kezar Life Sciences, KZR, Form 4, Stock Option, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership